Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Rodman & Renshaw starts Hemab Therapeutics at buy; PT $56

Rodman & Renshaw initiated coverage of Hemab Therapeutics (NASDAQ: COAG) with a “buy” rating and price target of $56.00. The stock closed at $31.62 on October 9. Hemab’s lead asset sutacimig is a bispecific...

October 13, 2026

Markets

Lucid starts Envoy Medical at buy; PT $2

Lucid Capital Markets initiated coverage of Envoy Medical (NASDAQ: COCH) with a “buy” rating and price target of $2.00. The stock closed at $0.66 on October 9. Envoy is a hearing health medical-device company developing...

October 13, 2026

Developments

Profound Medical and Telix Pharmaceuticals enter co-education agreement to advance PSMA-informed, MRI-guided and incisionless prostate care

Profound Medical (NASDAQ:PROF; TSX:PRN) and Telix Pharmaceuticals (ASX:TLX; NASDAQ:TLX) have entered into a co-education agreement which establishes a framework through which the companies intend to educate urologists...

October 9, 2026

Developments

As AI powers a U.S. nuclear buildout, Valion’s needle-free Entolimod could bring radiation preparedness to population scale

Rising electricity demand from AI and data centers is driving plans to expand nuclear power capacity, possibly including on-site small modular reactors (SMRs). This made international headlines earlier this week as...

October 9, 2026

Developments

Co-Diagnostics announces first Vector Smart lab for Native American tribe

Co-Diagnostics (NASDAQ: CODX) has announced that it has received an order from the Ute Indian Tribe Mosquito Abatement Department for a full Vector Smart mosquito surveillance laboratory installation. According to Co...

October 8, 2026

Developments

JPO issues NOA for bioAffinity’s CyPath Lung patent

bioAffinity Technologies (NASDAQ: BIAF) has announced that the Japan Patent Office (JPO) has issued a notice of allowance (NOA) indicating its intention to grant a patent covering bioAffinity’s non-invasive lung cancer...

October 8, 2026

Developments

Profound reports record preliminary Q3-2026 revenue; expects up to 89% YoY and 300% sequential QoQ growth; preliminary numbers exceed Bloomberg analyst consensus by 45% to 47%

Profound Medical (NASDAQ: PROF; TSX: PRN) announced preliminary unaudited revenues for the third quarter of 2026. The company indicated that its: Total revenue is expected to be in the range of $9.8 million to $10.0...

October 8, 2026

Developments

RenovoRx advances TAMP into borderline resectable PDAC

RenovoRX (NASDAQ: RNXT) has announced that the first patient has enrolled in PRISM-TAMP, an investigator-initiated trial sponsored by the University of Vermont (UVM) evaluating the approved chemotherapy gemcitabine...

October 7, 2026

Developments

PacBio and TychoBio collaborate to train AI models for rare disease therapeutics

PacBio (NASDAQ: PACB) and closely held TychoBio have announced a collaboration to generate full-length RNA data that TychoBio will use to train models for RNA therapy design. Under the terms of the agreement, TychoBio...

October 6, 2026

Developments

Saluda announces U.S. availability of first and only closed-loop surgical paddle

Saluda Medical (ASX: SLD) has announced the full U.S. commercial release of the FDA-approved CAP24 Surgical Paddle Lead making it available to neurosurgery and orthopedic spine practices in selected centers...

October 6, 2026

Executive Moves

Valion board chair Thomas Jensen brings biotech turnaround experience to advance Entolimod

Valion Bio (NASDAQ: VBIO) has outlined the perspectives of its new board chair, Thomas H. Jensen, on advancing Entolimod—an investigational Toll-like receptor 5 (TLR5) agonist being developed as a potential medical...

October 5, 2026

Developments

Wandercraft acquires Esko Bionics advancing robotic mobility

Closely held Wandercraft has announced the acquisition of Ekso Bionics from a subsidiary of ChronoScale Holdings Corporation (NASDAQ: CHRN), uniting two leaders in robotic mobility to form the world’s leading medical...

October 2, 2026

Subscribe